Impairment Due to Declining Profitability of Assets Used in the PXB Mouse Business
First written in FY2019. 4 of 8 entries say "Materialised", first in FY2019. Latest entry: FY2025.
The whole theme swung hardest in 2020: 51 of 96 companies on the "Worse" side.
- FY2025MaterialisedAnnual report
「As the company plans not to use the fixed assets held by the subsidiary in the future and instead to transfer or dispose of them, it decided to recognize an impairment loss on their carrying amount of ¥13,732 thousand and recorded it as an extraordinary loss.」
The company decided not to use KMT Hepatech,Inc.'s production equipment in the future and to transfer or dispose of it, resulting in the recognition of an impairment loss of ¥13,732 thousand. - FY2023-Q1Cited as achievedAnnual report
「Cost of sales was lower than in the same period of the previous year, mainly due to a decrease in outsourced costs for contract testing and a reduction in depreciation and amortization resulting from the recognition of an impairment loss on the overseas production facility in the previous period.」
The company cites the recognition of an impairment loss on the overseas production facility in the previous period as a historical factor behind the decrease in depreciation and amortization during the current quarter. - FY2022MaterialisedAnnual report
「In addition, after reviewing the future recoverability of the overseas production facility whose capital investment was completed in August 2020 based on its production results, the company was required to recognize an impairment loss on the full carrying amount of its property, plant and equipment, resulting in a net loss attributable to owners of the parent of ¥387,970 thousand.」
The decline in the profitability and recoverability of the overseas production facility resulted in an impairment loss on its full carrying amount of ¥265,027 thousand. - FY2020MaterialisedAnnual report
「In addition, following a revision of the business plan, the company recognized impairment losses on goodwill and fixed assets.」
Following the decline in the profitability of KMT Hepatech,Inc. in connection with the PXB mouse business, a new impairment loss of ¥292,122 thousand arose on goodwill and fixed assets. - FY2020-Q3RestatedAnnual report
「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company reconfirms that there were no new business or other risks and no material changes to the risks described in the previous fiscal year. - FY2020-Q2RestatedAnnual report
「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states that there were no new business or other risks and no material changes to the risks described in the previous fiscal year. - FY2020-Q1RestatedAnnual report
「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」
The company states that there were no material changes to the business and other risks described in the previous fiscal year. It does not indicate any new occurrence or expansion of the impairment risk relating to assets used in the business that arose in the previous period. - FY2019MaterialisedAnnual report
「During the consolidated fiscal year, the company reduced the carrying amount of assets used in the business to their recoverable amount due to declining profitability and recognized the decrease of ¥14,937 thousand as an impairment loss under extraordinary losses.」
The profitability of assets used in the PXB mouse business declined, and an impairment loss of ¥14,937 thousand was recognized.